-
公开(公告)号：US20100029554A1
公开(公告)日：2010-02-04
申请号：US12301199
申请日：2007-05-25
申请人： Soumitra S. Ghosh , Diana Y. Lewis , Samuel Janssen , Ved Srivastava , Que Liu , Carolyn M. Jodka , Christopher J. Soares , Qing Lin
发明人： Soumitra S. Ghosh , Diana Y. Lewis , Samuel Janssen , Ved Srivastava , Que Liu , Carolyn M. Jodka , Christopher J. Soares , Qing Lin
CPC分类号： C07K14/605 , A61K38/00 , C07K14/57563
摘要： Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects.
摘要翻译： 本文提供使用GLP-1分子或其激动剂及其类似物，以及使用毒蜥外泌肽分子或其激动剂及其类似物，包括其衍生物和活性片段来预防或治疗充血性心力衰竭。 还公开了用于本文所述方法的药物组合物。 还提供了用于治疗和/或预防糖尿病，高血糖症，胰岛素抵抗和肥胖以及减少食物摄取和抑制受试者食欲的组合物和方法。
-
2.发明授权Use of exendin and analogs thereof to delay or prevent cardiac remodeling 有权毒蜥外泌肽及其类似物的使用可延缓或预防心脏重塑公开(公告)号：US08946149B2
公开(公告)日：2015-02-03
申请号：US11910730
申请日：2006-04-11
申请人： Christen Anderson , Que Liu
发明人： Christen Anderson , Que Liu
IPC分类号： A61K38/26 , A61P9/10 , A61K38/22 , C07K14/605
CPC分类号： A61K38/26 , A61K38/2278
摘要： The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.
摘要翻译： 本发明一般涉及心脏保护性肠降血糖素化合物（CIC）如GLP-1和毒蜥外泌肽及其激动剂的新用途，包括类似物和衍生物以预防，延缓，减弱或改善心脏重塑。 本发明涉及使用CIC来治疗与心脏重塑有关的病症的方法。 本发明还涉及使用CIC降低充血性心力衰竭的风险或严重程度的方法。
-
3.发明申请Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling 有权使用GLP-1，毒蜥外泌肽和激动剂来延缓或预防心脏重塑公开(公告)号：US20090137466A1
公开(公告)日：2009-05-28
申请号：US11910730
申请日：2006-04-11
申请人： Christen Anderson , Que Liu
发明人： Christen Anderson , Que Liu
CPC分类号： A61K38/26 , A61K38/2278
摘要： The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.
摘要翻译： 本发明一般涉及心脏保护性肠降血糖素化合物（CIC）如GLP-1和毒蜥外泌肽及其激动剂的新用途，包括类似物和衍生物以预防，延缓，减弱或改善心脏重塑。 本发明涉及使用CIC来治疗与心脏重塑有关的病症的方法。 本发明还涉及使用CIC降低充血性心力衰竭的风险或严重程度的方法。
-
-
搜索结果
3 条记录 (耗时 0.03 秒)